View More Recent Stories
-
Denali Therapeutics (DNLI) Announces Successful Meeting with the FDA, Plans to File for Accelerated Approval of Tividenofusp Alfa
-
Denali Therapeutics (DNLI) Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform
-
Denali Therapeutics Inc. (DNLI) PT Lowered to $90 at H.C. Wainwright
-
Denali Therapeutics Inc. (DNLI) Tops Q2 EPS by 8c
